Peptidergic nootropic therapy in cerebral palsy associated with epilepsy

Abstract

Cortexin as add-on to AEDs reduced for more than two times the number of seizures, along with improvement of motor function, in 31 (36.9%) patients. The improvement of motor function, but without a significant decrease in epileptic seizures, was achieved in 15 (17.8%) of the patients. Reduction of epileptic seizures frequency (>2 times), but without a significant effect on motor function, was observed in 14 cases (16.7%). Twenty-three patients (27.4%) did not respond the therapy. The aggravation of epileptic seizures during cortexin therapy was observed in only 1 girl with West syndrome (1.2%), and this was significantly lower than the probability of seizures aggravation on AED. Polypeptide nootropic medication cortexin demonstrated efficacy and safety as adjunctive therapy in children with CP combined with epilepsy.

Cerebral palsy and epilepsy

“…Metabolic l-carnitine treatment is very useful for patients with cerebral palsy especially in cases of prolong antiepileptic therapy (extremely important in long-term therapy with valproates causing Cerebral Palsy and Epilepsy http://dx.doi.org/10.5772/intechopen.79565 carnitine deficiency). Peptidergic nootropic therapy in cerebral palsy associated with epilepsy also demonstrated its efficiency and safety [14].…”